Zacks: Brokerages Anticipate Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) to Announce -$0.21 EPS
Brokerages expect Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) to post ($0.21) earnings per share (EPS) for the current quarter, according to Zacks Investment Research. Three analysts have provided estimates for Vanda Pharmaceuticals’ earnings. The lowest EPS estimate is ($0.27) and the highest is ($0.14). Vanda Pharmaceuticals reported earnings of ($0.11) per share in the same quarter last year, which would suggest a negative year over year growth rate of 90.9%. The business is scheduled to announce its next earnings results after the market closes on Wednesday, August 2nd.
On average, analysts expect that Vanda Pharmaceuticals will report full-year earnings of ($0.65) per share for the current fiscal year, with EPS estimates ranging from ($0.77) to ($0.54). For the next fiscal year, analysts expect that the company will report earnings of ($0.29) per share, with EPS estimates ranging from ($0.58) to $0.13. Zacks’ earnings per share averages are an average based on a survey of research analysts that that provide coverage for Vanda Pharmaceuticals.
Vanda Pharmaceuticals (NASDAQ:VNDA) last released its earnings results on Tuesday, May 2nd. The biopharmaceutical company reported ($0.17) earnings per share for the quarter, missing the consensus estimate of ($0.13) by $0.04. Vanda Pharmaceuticals had a negative net margin of 8.85% and a negative return on equity of 10.42%. The firm had revenue of $37.42 million during the quarter, compared to the consensus estimate of $38.35 million.
VNDA has been the topic of a number of research reports. Oppenheimer Holdings, Inc. initiated coverage on Vanda Pharmaceuticals in a report on Wednesday, April 12th. They set an “outperform” rating and a $21.00 price objective on the stock. Zacks Investment Research cut Vanda Pharmaceuticals from a “hold” rating to a “strong sell” rating in a report on Tuesday, July 18th. Piper Jaffray Companies reissued an “overweight” rating and set a $23.00 price objective on shares of Vanda Pharmaceuticals in a report on Tuesday, June 27th. Jefferies Group LLC reissued a “buy” rating and set a $21.00 price objective on shares of Vanda Pharmaceuticals in a report on Thursday, May 25th. Finally, TheStreet raised Vanda Pharmaceuticals from a “d+” rating to a “c-” rating in a report on Friday, May 12th. One equities research analyst has rated the stock with a sell rating and eight have assigned a buy rating to the company’s stock. Vanda Pharmaceuticals has an average rating of “Buy” and an average price target of $21.22.
A number of institutional investors have recently made changes to their positions in the company. State Street Corp boosted its position in shares of Vanda Pharmaceuticals by 27.2% in the fourth quarter. State Street Corp now owns 1,751,605 shares of the biopharmaceutical company’s stock worth $27,935,000 after buying an additional 374,095 shares during the period. Cheyne Capital Management UK LLP boosted its position in shares of Vanda Pharmaceuticals by 42.3% in the first quarter. Cheyne Capital Management UK LLP now owns 74,000 shares of the biopharmaceutical company’s stock worth $1,034,000 after buying an additional 22,000 shares during the period. Weiss Multi Strategy Advisers LLC boosted its position in shares of Vanda Pharmaceuticals by 20.0% in the first quarter. Weiss Multi Strategy Advisers LLC now owns 60,000 shares of the biopharmaceutical company’s stock worth $840,000 after buying an additional 10,000 shares during the period. FMR LLC boosted its position in shares of Vanda Pharmaceuticals by 928.0% in the fourth quarter. FMR LLC now owns 996,271 shares of the biopharmaceutical company’s stock worth $15,891,000 after buying an additional 899,358 shares during the period. Finally, Prudential Financial Inc. boosted its position in shares of Vanda Pharmaceuticals by 0.8% in the first quarter. Prudential Financial Inc. now owns 614,318 shares of the biopharmaceutical company’s stock worth $8,600,000 after buying an additional 4,700 shares during the period. 92.51% of the stock is currently owned by institutional investors and hedge funds.
WARNING: “Zacks: Brokerages Anticipate Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) to Announce -$0.21 EPS” was published by American Banking News and is owned by of American Banking News. If you are viewing this piece of content on another site, it was copied illegally and republished in violation of U.S. and international copyright and trademark legislation. The original version of this piece of content can be viewed at https://www.americanbankingnews.com/2017/07/27/zacks-brokerages-anticipate-vanda-pharmaceuticals-inc-nasdaqvnda-to-announce-0-21-eps.html.
Vanda Pharmaceuticals (NASDAQ:VNDA) traded down 0.156% during trading on Thursday, hitting $15.975. 36,968 shares of the company traded hands. Vanda Pharmaceuticals has a 12-month low of $11.00 and a 12-month high of $18.00. The stock has a 50-day moving average price of $15.67 and a 200-day moving average price of $14.56. The firm’s market capitalization is $711.72 million.
About Vanda Pharmaceuticals
Vanda Pharmaceuticals Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies to address unmet medical needs. Its product portfolio includes HETLIOZ (tasimelteon), Fanapt (iloperidone), Tradipitant (VLY-686), Trichostatin A and AQW051. It offers HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Vanda Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.